NCT02516605已完成2 期
A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 29
- 主要终点
- Haemoglobin
研究概览
简要总结
A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Diagnosis of PBC as demonstrated by the presence of at least 2 of the following 3 diagnostic criteria:
- •History of alkaline phosphatase (ALP) elevated above upper limit of normal (ULN) for at least 6 months
- •Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex))
- •Previous liver biopsy findings consistent with PBC
- •At least 1 of the following markers of disease severity:
- •ALP ≥ 1.67 × ULN
- •Total bilirubin > ULN but < 1.5 × ULN
- •In addition, patients must meet the following biochemical criteria at enrollment:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 × ULN
- •Total bilirubin ≤ 1.5 × ULN
- •INR ≤ ULN
- •Taking UDCA for at least 12 months, or for at least 6 months and has reached maximal response to UDCA with a plateau in alkaline phosphatase, with no changes in dose for ≥ 3 months prior to Day
- •Patients must weigh at least 40 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 40 kg/m
- •BMI = Body weight (kg) / [Height (m)]2
排除标准
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception for 30 days before randomization, during dosing and for 30 days following the end of treatment.
- •Presence of other concomitant liver diseases.
- •Cirrhosis with complications, including history or presence of:
- •Variceal bleed
- •Uncontrolled ascites
- •Encephalopathy
- •Spontaneous bacterial peritonitis
- •Significant hepatic impairment as defined by Child-Pugh classification of B or C, history of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score ≥
- •History of conditions that may cause increases in ALP (e.g., Paget's disease).
- •Use of investigational drugs, or immunosuppressive drugs at the time of enrollment, or within 5 half-lives, or 30 days of randomization, whichever is longer; or longer if required by local regulations. Use of high dose oral steroids to treat co-morbid conditions (e.g., airways disease) will be allowed but must be properly documented as such in concomitant medications.
- •Currently taking obeticholic acid or have taken obeticholic acid within 30 days of randomization
- •Previous participation in CLJN452X2201 and received study medication within three months of randomization (or longer if required by local regulations).
结局指标
主要结局
Haemoglobin
时间窗: Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Hematology panel for safety laboratory assessments.
ECG - Heart Rate
时间窗: Screening, Baseline, day 1, day 28
Electrocardiogram (ECG)
Fold Change in Serum Gamma-glutamyl Transferase (GGT)
时间窗: Baseline to Day 28
Fold change in serum gamma-glutamyl transferase (GGT) from baseline to Day 28
Blood Pressure
时间窗: Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Vital signs - Systolic Blood pressure
Pulse Rate
时间窗: Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Vital signs
Body Temperature
时间窗: Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Vital signs
ECG Intervals - PR Interval
时间窗: Screening, Baseline, day 1, day 28
Electrocardiogram (ECG)
次要结局
- Plasma PK Parameter - Cmax(Day 1, Day 28)
- Change From Baseline in Global Itch Visual Analogue Scale (VAS)(Day 7, Day 14, Day 21, Day 28, Day 56, and Day 84)
- Plasma PK Parameter - AUC 0-8h(Day 1, Day 28)
- Change From Baseline in Itch Subdomain of PBC-40 Score(Baseline, Day 28, Day 56, Day 84)
- Plasma PK Parameter - Tmax(Day 1, Day 28)
- Changes From Baseline in Total PBC-40 Score(Baseline, Day 28, Day 56, Day 84)
研究者
研究点 (29)
Loading locations...
相似试验
终止
2 期
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)Non-alcoholic Steatohepatitis (NASH)NCT02855164Novartis Pharmaceuticals350
已完成
1 期
The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.Liver DiseaseNCT04408937Novartis Pharmaceuticals89
已完成
2 期
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive DisorderDepressive Disorder, MajorNCT00057213GlaxoSmithKline367
已完成
2 期
An 8 Week Study Of Adults Diagnosed With Major Depressive DisorderDepressive Disorder, MajorNCT00057226GlaxoSmithKline365
已完成
2 期
Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLCAdvanced Non-small Cell Lung CancerNCT00385606National Cancer Institute, Naples400